Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFOL-09 of rinatabart sesutecan in advanced gastrointestinal cancers
jRCT2051260087Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rinatabart sesutecan in gastrointestinal cancer, sponsored by Genmab. Primary endpoint: Confirmed Objective Response Rate. Started Jul 2026; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on jRCT2051260087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260087.